The neural crest is a migratory population of embryonic cells with a tremendous potential to
differentiate and contribute to nearly every organ system in the adult body. Over the past two …

Therapeutics that target ERBB2, such as lapatinib, often provide initial clinical benefit, but
resistance frequently develops. Adaptive responses leading to lapatinib resistance involve …

Neural crest induction involves the combinatorial inputs of the FGF, BMP and Wnt signaling
pathways. Recently, a two-step model has emerged where BMP attenuation and Wnt …

Targeting the dysregulated BRAF–MEK–ERK pathway in cancer has increasingly emerged
in clinical trial design. Despite clinical responses in specific cancers using inhibitors …

The central role of the BRAF–MEK–ERK pathway in controlling cell fate has made this pathway
a primary target for deregulated activation in cancer. BRaf is activated by Ras proteins …

Background Glioblastoma (GBM) is the most common and aggressive primary brain tumor.
Prognosis remains poor despite multimodal therapy. Developing alternative treatments is …

Rationale: Cystic fibrosis (CF) lung disease is caused by the loss of function of the cystic
fibrosis transmembrane conductance regulator (CFTR) combined with hyperactivation of the …

Synergistic inhibition of BDs encoded in BAZ2A/B, BRD9, and BET proteins induces
apoptosis of TNBC by a combinatorial suppression of ribosomal DNA transcription and ETS-…

Background Most novel cancer therapeutics target kinases that are essential to tumor survival.
Some of these kinase inhibitors are associated with cardiotoxicity, whereas others appear …

Inhibition of the HER2/ERBB2 receptor is a keystone to treating HER2-positive malignancies,
particularly breast cancer, but a significant fraction of HER2-positive (HER2+) breast …